Measurement of inflammatory cytokines in patients with rheumatoid arthritis

Korean Journal of Laboratory Medicine

Volumn 30, Issue 3, 2010, Pages 301-306

  Kang, So Young ^a   Kim, Myeong Hee ^a   Lee, Woo In ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Disease activity; Interleukin 6; Rheumatoid arthritis; Tumor necrosis factor alpha

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTERLEUKIN-6; METHOTREXATE; MIDDLE AGED; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955499776     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2010.30.3.301     Document Type: Article

References (22)

1. Park JY and Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65(Suppl 1): 54-10.
2. Ringold S and Singer NG. Measures of disease activity in rheumatoid arthritis: a clinician's guide. Curr Rheumatol Rev 2008; 4: 259-65.
3. da Mota LM, dos Santos Neto LL, de Carvalho JF. Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity? Clin Rheumatol 2009; 28: 1127-34.
4. Sir JU and Kim TY. Can polymerized C9 be a new disease activity parameter in rheumatoid arthritis? J Korean Rheum Assoc 2005; 12: 206-12.
5. Soubrier M and Dougados M. Selecting criteria for monitoring patients with rheumatoid arthritis. Joint Bone Spine 2005; 72: 129-34.
6. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008; 31: 175-9.
7. Tian H and Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65: 168-73.
8. Ranganathan P and McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006; 54: 1366-77.
9. Swierkot J and Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006; 58: 473-92.
10. Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998; 9: 145-54.
11. Cronstein BN. Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65 (Suppl 1): S11-5.
12. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232-4.
13. Straub RH, Muller-Ladner U, Lichtinger T, Scholmerich J, Menninger H, Lang B. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol 1997; 36: 1298-303.
14. Dasgupta B, Corkill M Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992; 19: 22-5.
15. Jeon CH, Kim JH, Park JH, Ahn KS, Kim HJ, Kim EH, et al. Cytokine profiles in synovial fluid of rheumatoid arthritis. Korean J Med 2003; 64: 576-87.
16. Petrovic-Rackov L and Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol 2006; 25: 448-52.
17. Brennan FM and Mclnnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-45.
18. Emery P, Gabay Q Kraan M Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007; 27: 793-806.
19. Barrera P, Boerbooms AM Janssen EM Sauerwein RW, Gallati H, Mulder J, et aL Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070-9.
20. Barrera P, Haagsma CJ, Boerbooms AM Van Riel PL Borm GF, Van de Putte LB, et al. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 1995; 34: 747-55.
21. Gabay G Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8(Suppl2): S3.
22. Sugiyama E, Kuroda A, Hori F, Hori T, Taki H, Arai N, et al. Serum interleukin-6 level is a sensitive parameter of disease activity in rheumatoid arthritis. J Clin Rheumatol 1995; 1: 93-8.